Laura Martinez Alarcon

Lucas-Ruiz F, Mateo SV, Jover-Aguilar M, Alconchel F, Martinez-Alarcon L, de Torre-Minguela C, Vidal-Correoso D, Villalba-Lopez F, Lopez-Lopez V, Rios-Zambudio A, Pons JA, Ramirez P, Pelegrin P, Baroja-Mazo A. Danger signals released during cold ischemia storage activate NLRP3 inflammasome in myeloid cells and influence early allograft function in liver transplantation. EBioMedicine. 2023 Jan;87:104419. doi: 10.1016/j.ebiom.2022.104419. Epub 2022 Dec 19. PubMed PMID: 36543018; PubMed Central PMCID: PMC9794897.

AÑO: 2023; IF: 11.1

36543018

Hernandez-Caravaca I, Moros-Nicolas C, Gonzalez-Brusi L, Romero de Avila MJ, De Paco Matallana C, Pelegrin P, Castano-Molina MA, Diaz-Meca L, Sanchez-Romero J, Martinez-Alarcon L, Aviles M, Izquierdo-Rico MJ. Colostrum Features of Active and Recovered COVID-19 Patients Revealed Using Next-Generation Proteomics Technique, SWATH-MS. Children (Basel). 2023 Aug 21;10(8):1423. doi: 10.3390/children10081423. PubMed PMID: 37628421; PubMed Central PMCID: PMC10453012.

AÑO: 2023; IF: 2.4

37628421

Lopez-Lopez V, Hiciano-Guillermo A, Martinez-Alarcon L, Delegido A, Alconchel F, Pons JA, Fernandez JA, Rios A, Rodriguez JM, Miura K, Sanchez-Bueno F, Robles-Campos R, Ramirez P. Postoperative negative-pressure incision therapy after liver transplant (PONILITRANS study): A randomized controlled trial. Surgery. 2023 Apr;173(4):1072-1078. doi: 10.1016/j.surg.2022.11.011. Epub 2022 Dec 20. PubMed PMID: 36549975.

AÑO: 2023; IF: 3.8

36549975

Villalba-Lopez F, Garcia-Bernal D, Mateo SV, Vidal-Correoso D, Jover-Aguilar M, Alconchel F, Martinez-Alarcon L, Lopez-Lopez V, Rios-Zambudio A, Cascales P, Pons JA, Ramirez P, Pelegrin P, Baroja-Mazo A. Endothelial cell activation mediated by cold ischemia-released mitochondria is partially inhibited by defibrotide and impacts on early allograft function following liver transplantation. Biomed Pharmacother. 2023 Sep 18;167:115529. doi: 10.1016/j.biopha.2023.115529. Online ahead of print. PubMed PMID: 37729732.

AÑO: 2023; IF: 7.5

37729732

Hurtado-Navarro L, Cuenca-Zamora EJ, Zamora L, Bellosillo B, Such E, Soler-Espejo E, Martinez-Banaclocha H, Hernandez-Rivas JM, Marco-Ayala J, Martinez-Alarcon L, Linares-Latorre L, Garcia-Avila S, Amat-Martinez P, Gonzalez T, Arnan M, Pomares-Marin H, Carreno-Tarragona G, Chen-Liang TH, Herranz MT, Garcia-Palenciano C, Morales ML, Jerez A, Lozano ML, Teruel-Montoya R, Pelegrin P, Ferrer-Marin F. NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy. Cell Rep Med. 2023 Dec 19;4(12):101329. doi: 10.1016/j.xcrm.2023.101329. PubMed PMID: 38118408.

AÑO: 2023; IF: 14.3

38118408